Observational studyPediatric nephrology (Berlin, Germany)2025

Telitacicept as a BAFF/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis.

Yanyan Jin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.